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• Group 3 comprised a comparative cohort 
of patients treated with primary RNU for 





• Groups 1, 2 and 3 included 18, 120 and 
175 patients, respectively. The 5-year 
disease-free survival rates were 49%, 
30% and 64%, whereas the 5-year 
cancer-specific survival rates were 44%, 
36% and 69% in groups 1, 2 and 3, 
respectively.
• In group 1, on final pathological 
evaluation, nine patients were pN0, six 
patients were pT0 and five patients had 
pT0N0 disease. Kaplan–Meier survival 
analyses showed similar recurrence and 

















 0.06, respectively). 
• Meanwhile, group 2 had significantly 
lower disease-free and cancer-specific 
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• Preoperative chemotherapy followed by 
aggressive surgical consolidation may yield 
favourable oncological outcomes in patients 
with UTUC with loco-regional nodal 
metastases.
• These data support further evaluation of 
neoadjuvant systemic therapy in patients at 




urothelial carcinoma, chemotherapy, lymph 
node metastases
 
What’s known on the subject? and What does the study add?
 
Neoadjuvant chemotherapy offers survival benefits for patients with urothelial carcinoma 
of the bladder. However, it is still underutilized in the ‘biologically similar’ upper tract 
urothelial carcinoma. Systemic chemotherapy in a neoadjuvant setting is a more 
attractive option, as loss of renal function after nephrectomy can complicate the 
administration of adjuvant chemotherapy. We found that preoperative systemic therapy 
followed by aggressive surgical debulking is a promising treatment strategy for upper 
tract urothelial carcinoma patients with known or at risk of loco-regional nodal 
metastasis.
Study Type – Therapy (multi-
insititutional cohort)




• To describe a multicentre experience with 
preoperative platinum-based chemotherapy 
before radical nephroureterectomy (RNU) in 
patients with upper tract urothelial 





• We identified 313 patients from the 
UTUC Collaboration (over 1200 patients), 
who underwent RNU with concomitant 
retroperitoneal lymph node dissection 
between 1990 and 2007 and met the 
inclusion criteria for one of three 
groups.
• Group 1 comprised patients who received 
chemotherapy before RNU because of 
biopsy-proven loco-regional nodal 
metastases. 
• Group 2 consisted of patients who 
underwent primary RNU and were found to 
have metastatic nodal disease on final 
pathological review (node-positive). 
BJUI
 
B J U  I N T E R N A T I O N A L
 






2 0 11  T H E  A U T H O R S




 2 0 11  B J U  I N T E R N A T I O N A L
 




Upper urinary tract urothelial carcinoma 
(UTUC) is relatively rare, accounting for 
approximately 5% of genitourinary 
malignancies, although recent data suggest 
that the incidence is increasing [1,2]. Radical 
nephroureterectomy (RNU) with excision of 
an ipsilateral bladder cuff via a laparoscopic 
or open approach remains the standard 
treatment in patients with invasive UTUC 
and a functional contralateral kidney. 
Although surgical techniques have improved, 
locally advanced UTUC still has a poor 
prognosis and systemic recurrences are 
common [2–4].
Unfortunately, with the rarity of the disease 
and historical difficulties in gathering patients 
with urothelial carcinoma for clinical trials, 
there are very few direct data providing 
clinical guidance on the optimal management 
of patients diagnosed with locally advanced 
UTUC. Small series show measurable response 
rates, specifically in patients treated with 
chemotherapy for metastatic or unresectable 
UTUC [5]. The loss of renal function that 
occurs with nephrectomy can complicate the 
administration of appropriate systemic 
chemotherapy in an adjuvant setting. 
Uncertainties regarding the survival benefit 
gained from chemotherapy combined with 
inadequacy of clinical staging are additional 
contributing factors that have led to the 
under-use of neoadjuvant chemotherapy for 
UTUC. However, analogous to the experience 
with urothelial carcinoma of the bladder 
(UCB), where administration of neoadjuvant 
cisplatin-based combination chemotherapy 
translated into a tangible survival advantage 
[6], it is argued that preoperative systemic 
chemotherapy should be used in patients with 
locally advanced UTUC [6,7].
Patients with UTUC and loco-regional nodal 
metastatic disease represent a challenging 
cohort of patients, with no randomized trials 
to guide their optimal management. Using a 
multi-institutional database of patients 
treated for UTUC, we evaluated the 
oncological outcomes in patients with UTUC 
and loco-regional nodal metastases treated 
with preoperative systemic therapy followed 
by aggressive surgical consolidation with 
RNU. Oncological outcomes were compared 
with node-positive patients treated with 
immediate RNU and with node negative (N0) 
patients with locally advanced UTUC 




We used a database comprising patients from 
the UTUC Collaboration, this patient cohort 
has been described in detail elsewhere [3]. 
After combining the data sets from the 
enrolled centres, a database containing more 
than 1200 patients who underwent RNU with 
ipsilateral bladder cuff resection between 
1987 and 2007 was generated. We identified 
313 patients who met the criteria for one of 
three groups. Group 1 comprised patients 
who had clinical evidence of positive loco-
regional nodal metastases, confirmed by 
biopsy. These patients received preoperative 
chemotherapy followed by RNU. Group 2 
consisted of patients who underwent primary 
RNU and were found to have metastatic nodal 
disease on final pathological review. Group 3 
comprised a comparative cohort of patients 
treated with primary RNU for (pT2-T4N0) 
UTUC. Selection criteria required adequate 
pathological staging with standard, rather 
than limited, lymph node dissection during 
RNU. Adequate pathological nodal staging 
was defined as removal of the para-aortic, 
paracaval, or interaortocaval nodes from the 
renal hilum to the inferior mesenteric artery 
for renal pelvis and proximal ureteral 
tumours. For mid- and lower ureteral 
tumours, lymph node dissection was 
performed from the renal hilum to the 
bifurcation of the common iliac artery and 
ipsilateral pelvic nodes, respectively. The 
standardization of lymph node dissection was 
impossible because of the multicentre and 
retrospective study design. As a result of 
inadequate regional lymphadenectomy (as 
reported by individual contributing centres), 
223 patients were excluded from further 
analysis.
All surgical specimens were processed 
according to standard pathological 
procedures, and all slides were re-reviewed by 
genitourinary pathologists according to 
prospectively defined uniform criteria. All 
pathologists were blinded to clinical 
outcomes. Tumours were staged according to 
the American Joint Committee on Cancer – 
Union International Contre le Cancer (AJCC-
UICC) Tumor-Node-Metastasis (TNM) 
classification 2002 [8]. Tumour grading was 
assessed according to the 1998 WHO/
International Society of Urologic Pathology 
(ISUP) consensus classification [9]. In addition, 
all specimens were evaluated for tumour 
location, pattern of tumour growth (papillary 
vs sessile), presence of lymphovascular 






Follow up was performed according to 
institutional protocols. Patients were 
generally followed every 3 months for the 
first year after RNU and every 6 months from 
the second year. Follow up consisted of a 
history, physical examination, routine blood 
work and serum chemistry studies, urinary 
cytology, chest radiography, cystoscopic 
evaluation of the urinary bladder, and 
radiographic evaluation of the contralateral 
upper urinary tract. Elective bone scans, chest 
CT or MRI were taken when clinically 
indicated.
Statistical analysis was performed with SPSS 
version 17 (SPSS, Chicago, IL, USA). Bladder 
recurrences were not considered in the 
analysis of disease-free survival rate. Disease-
free survival and cancer-specific survival were 
estimated using the Kaplan–Meier survival 
analysis. Disease recurrence was defined as 
local failure in the nephroureterectomy bed, 
regional lymph nodes, or distant metastasis 
after RNU for UTUC. The period of disease-
free survival was defined as the time between 
the date of RNU and the development of local 
recurrence or distant metastasis. Censored 
survival values represent patients who were 
alive without clinical evidence of disease at 
the last follow-up. Cause of death was 
determined by the treating physicians, by 
chart review corroborated by death 
certificates, or by death certificates alone. The 
period of cancer-specific survival was defined 
as the time between the date of RNU and 
death due to cancer. Statistical differences 





 values are two-sided and 








Table 1 describes clinical characteristics of the 
patients according to the study grouping. 
Preoperative systemic chemotherapy 
regimens consisted of gemcitabine/
cisplatinum in 14 patients, methotrexate, 
vinblastine, doxorubicin and cisplatin (MVAC) 
in four patients. The patients in group 1 
received two to nine preoperative 
chemotherapy cycles (median six cycles). 
Three of the 18 patients in this group, 
received additional adjuvant chemotherapy. 
Patients in groups 2 and 3 were managed 
with initial RNU (with open technique in 87% 
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and 86% of cases, respectively) followed by 
adjuvant chemotherapy in 43% and 19% of 
patients, respectively. Adjuvant chemotherapy 
regimens consisted of MVAC in 60%, 
gemcitabine/cisplatinum in 20% and other 
platinum-based regimens in the remaining 
20% of patients. On average, three cycles of 
adjuvant chemotherapy were administered 
(range one to six). Adjuvant systemic 
therapies were more likely to be used in 
younger patients as well as in patients 





, pT4Nany, pT3Nany). Table 2 
describes the pathological characteristics in 
each group. In group 1, nine patients were 
pN0, six patients were pT0 and five patients 
had pT0N0 disease on final pathological 
evaluation.
Figures 1 and 2 compare the probability of 
disease-free and cancer-specific survival 
among the study groups. The 5-year disease-
free survival rates were 49%, 30% and 64%, 
and the 5-year cancer-specific survival rates 
were 44%, 36% and 69% in groups 1, 2 and 3, 
respectively. Kaplan–Meier survival analyses 
showed similar recurrence and survival 

















 0.06, respectively). 
Meanwhile, group 2 had significantly lower 
disease-free survival and cancer-specific 
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respectively). Patients with no residual disease 
at RNU (pT0pN0) showed 83% 5-year cancer-
specific survival, compared with 31% for 










On multivariable Cox proportional hazards 
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UTUC and UCB share similar histological, 
biological, as well as molecular oncogenic 
characteristics and show comparable 
oncological outcomes when adjusted for 
tumour stage and grade [6,7]. Previous 
studies have shown a survival advantage in 
patients with UCB managed with neoadjuvant 
cisplatin-based combination chemotherapy 
before cystectomy [6,10]. Can this survival 
advantage be extrapolated to appropriately 
selected patients with UTUC? Unfortunately, 
conclusive data to support the use of 
neoadjuvant chemotherapy before RNU for 
UTUC are lacking. Moreover, unlike in UCB, 
clinical staging of patients with UTUC is of 
limited use, presenting additional difficulties 
in accurate selection of patients for 
neoadjuvant systemic therapy before RNU. 
Specifically, unlike in UCB, the depth of 




Clinical characteristics of 313 patients managed for advanced upper urinary tract urothelial 































Female 9 (50) 78 (65) 117 (67) 204 (65)





























0 10 (55.5) 79 (66) 111 (63) 200 (64)
1 7 (39) 35 (29) 61 (35) 103 (33)
2 1 (5.5) 6 (5) 3 (2) 10 (3)





Absent 10 (55.5) 94 (78) 140 (80) 244 (78)






Open 17 (94.5) 104 (87) 150 (86) 271 (86.5)






Neoadjuvant 18 (100) 0 0 18 (6)






Recurrence 8 (44) 78 (65) 59 (34) 145 (46)
Death due to cancer 7 (39) 66 (55) 48 (27) 121 (39)
 




, node-positive; N0, node-negative; RNU, radical 




Disease-free survival after radical 
nephroureterectomy in 313 patients managed for 
advanced upper urinary tract urothelial carcinoma, 
according to treatment group.
5Year-DFS P VALUE
Group 1 49% ± 10
Group 2 30% ± 5
Group 3 64% ± 4
0.04 (vs. group 2)
0.001 (vs. group 3)




Group 1 Preoperative therapy before RNU
Group 2 RNU (N+)
Group 3 RNU (N0)



























Cancer-specific survival after radical 
nephroureterectomy in 313 patients managed for 
advanced upper urinary tract urothelial carcinoma, 
according to treatment group.
5 Year-CSS P VALUE
Group 1 44% ± 16
Group 2 35% ± 5
Group 3 69% ± 4
0.06 (vs. group 2)
0.001 (vs. group 3)




Group 1 Preoperative therapy before RNU
Group 2 RNU (N+)
Group 3 RNU (N0)
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are difficult to ascertain with delicate 
endoscopic instruments designed for the 
upper urinary tract. In an ongoing Phase II 
clinical trial of neoadjuvant systemic therapy 
for UTUC, all patients with high-grade UTUC 
are offered systemic chemotherapy before 
surgery, because of the high correlation 
between high tumour grade and advanced 
pathological stage [11]. Alternatively, we have 
recently developed a preoperative nomogram, 
using grade, architecture and location of the 
tumour to predict the probability of non-
organ-confined UTUC [12]. If validated 
prospectively, this tool can be used for 
selection of patients to receive systemic 
therapy before RNU.
The results of this study suggest that 
favourable oncological outcomes can be 
achieved in patients with UTUC and loco-
regional nodal metastases treated with 
preoperative systemic therapy followed by 
aggressive surgical consolidation with RNU. 
This is shown by a significant rate of complete 
pathological responses achieved in both 
primary tumours and lymph nodes, as well as 
by the favourable survival observed in node-
positive patients treated with preoperative 
chemotherapy before consolidative RNU, 
compared with node-positive patients treated 
with initial surgery. Ultimately, the safety and 
efficacy of such an approach should be 
evaluated in the context of a prospective 
clinical trial [11].
In UCB, the advantages of neoadjuvant 
chemotherapy include timely treatment of 
systemic micrometastatic disease; significant 
rates of complete pathological responses in 
the bladder and decrease in positive surgical 
margins [1]. In UTUC, several unique disease 
features lend additional rationale for the use 
of neoadjuvant, rather than the adjuvant, 
chemotherapy in these patients. The loss of 
renal function that occurs with RNU can 
significantly complicate administration of 
appropriate adjuvant chemotherapy after 
surgery, especially in the elderly patient 
population, who are likely to have a multitude 
of associated comorbidities. Hence, the 
additional advantages of administering 
chemotherapy before RNU include better 
treatment tolerance and the ability to deliver 
higher treatment doses than in the adjuvant 
setting [7]. Despite concerns about increased 
surgical morbidity after preoperative 
chemotherapy, the data in patients with UCB 
have not supported this idea [13,14]. 
Proposed benefits of preoperative 
chemotherapy have to be carefully balanced 
against the risks of overtreatment and delay 
of potentially curative surgical intervention. 
Isolated clinical pathological parameters, such 
as tumour stage and grade, are not adequate 
for accurate assessment of the true disease 
burden so integrative staging tools, similar to 
a recently developed preoperative nomogram 
for prediction of non-organ-confined UTUC 
can guide patient selection for neoadjuvant 
chemotherapy [12].
Unfortunately, our data suggest that 
systemic chemotherapy continues to be 




50% of node-positive patients receiving 
chemotherapy before or after RNU. The 
reasons for this underutilization remain 
unclear, but probably include physician 
practice patterns, unwillingness by patients 
to undergo chemotherapy, and significant 




Pathological characteristics of 313 patients managed for advanced upper urinary tract 































Right 7 (39) 47 (39) 82 (47) 136 (43.5)
Left 11 (61) 73 (61) 93 (53) 177 (56.5)





Renal pelvis 15 (83.5) 87 (72.5) 108 (62) 210 (67)
Ureter 1 (5.5) 31 (26) 63 (36) 95 (30)






Papillary 3 (17) 53 (44) 115 (66) 171 (55)






Low 2 (11) 3 (2.5) 40 (23) 45 (14.5)
High 16 (89) 117 (97.5) 135 (77) 268 (85.5)





T0 6 (33) 0 (0) 0 (0) 6 (2)
T1 0 (0) 6 (5) 0 (0) 6 (2)
T2 3 (17) 19 (16) 61 (35) 83 (26)
T3 7 (39) 66 (55) 108 (62) 181 (58)






Absent 11 (61) 70 (58) 116 (66) 197 (63)






Absent 10 (55.5) 53 (44) 115 (66) 178 (57)






0 9 (50) 0 (0) 175 (100) 184 (59)
1 4 (22) 94 (78) 0 (0) 98 (31)
2 5 (28) 26 (22) 0 (0) 31 (10)
Mean no. of removed LNs (range) 13 (1–35) 6 (1–41) 7 (1–27) 7 (1–41)






Absent 11 (61) 35 (29) 106 (61) 152 (48.5)
Present 7 (39) 85 (71) 69 (39) 161 (51.5)
 




, node-positive; N0, node-
negative; RNU, radical nephroureterectomy.
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Based on our findings, as well as on 
experience gained from the management of 
patients with advanced UCB, preoperative 
platinum-based chemotherapy should be 
prospectively explored and incorporated 
into treatment algorithms of patients with 
advanced UTUC. We believe that an 
aggressive strategy with preoperative 
chemotherapy followed by RNU including 
meticulous lymph node dissection [15–17] 
may improve the outcome of these 
patients.
The data presented here are descriptive and 
exploratory, and several limitations of this 
study merit further discussion. First, are the 
limitations inherent to the retrospective 
study design, which undoubtedly translate 
into a significant selection bias and a 
disproportionally small number of patients 
in the preoperative chemotherapy group. 
Moreover, the number of patients treated 
with preoperative chemotherapy that could 
undergo subsequent RNU because of 
disease progression or declining 
performance status is not known. In 
addition, the true number of patients with 
clinically positive regional lymphadenopathy 
who did not undergo diagnostic biopsy and 
were managed with chemotherapy and 
surgery is not known. Finally, the patients 
with UTUC who were included in this study 
were managed by multiple surgeons who 
used different surgical techniques and 
templates of lymph node dissection. 
However, there was no established standard 
of care with regard to the performance and 
the extent of lymph node dissection during 
RNU at the time of study [18]. We believe 
that, with the rarity of UTUC, a 
retrospective study design, in which 
rigorous clinical and pathological review of 
patient data from multiple high-volume 
cancer centres is implemented, provides 
valuable clinical information, and serves as 
an important link into thoughtful 
prospective clinical trial design.
Preoperative systemic therapy followed by 
aggressive surgical consolidation may 
afford favourable oncological outcomes in 
patients with UTUC with loco-regional 
nodal metastases. This approach 
represents a promising treatment strategy 
for patients with UTUC with known 
loco-regional nodal metastasis or for 
those at risk of such metastases and 
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